Daewoong Pharma (069620.KS)
Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.
Company Info
Highlights
₩1.87T
₩1.08T
₩555.02B
₩106,480.16 - ₩171,600.00
₩201,875.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of ₩10,000 in Daewoong Pharma, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading data...
Returns By Period
Daewoong Pharma (069620.KS) has returned 27.77% so far this year and 31.41% over the past 12 months. Over the last ten years, 069620.KS has returned 4.90% per year, falling short of the S&P 500 benchmark, which averaged 11.49% annually.
069620.KS
- YTD
- 27.77%
- 1M
- 2.02%
- 6M
- 23.66%
- 1Y
- 31.41%
- 3Y*
- -2.63%
- 5Y*
- 8.74%
- 10Y*
- 4.90%
^GSPC (Benchmark)
- YTD
- 6.43%
- 1M
- 4.73%
- 6M
- 7.43%
- 1Y
- 11.48%
- 3Y*
- 17.91%
- 5Y*
- 14.47%
- 10Y*
- 11.49%
Monthly Returns
The table below presents the monthly returns of 069620.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
Based on daily data since Nov 2002, the average daily return (also called the expected return) is 0.09%, while the average monthly return is 1.79%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 8.94% | -7.92% | -10.88% | 22.12% | 15.00% | -9.26% | 12.99% | 28.72% | |||||
| 2024 | -5.22% | 3.52% | 5.85% | -7.75% | -4.47% | -4.21% | 21.68% | 20.39% | -7.80% | 14.97% | -22.96% | 3.69% | 8.75% |
| 2023 | -3.91% | -23.37% | -9.85% | 4.94% | 0.09% | -12.85% | 5.92% | 2.25% | 8.15% | -11.44% | 5.01% | 11.34% | -26.31% |
| 2022 | -11.82% | 27.20% | -1.20% | 11.59% | -6.01% | 2.62% | 3.97% | -4.36% | -9.97% | 2.22% | -8.67% | 7.87% | 7.51% |
| 2021 | -8.18% | -10.56% | -1.48% | 0.00% | 14.98% | 12.05% | -0.58% | -2.92% | -12.35% | -3.78% | -5.36% | 12.15% | -9.94% |
| 2020 | -14.18% | -11.02% | -19.33% | 26.33% | -4.21% | 29.27% | -16.98% | 5.45% | -9.48% | -13.14% | 13.49% | 60.04% | 20.47% |
| 2019 | 2.65% | 0.26% | -5.15% | 10.33% | -24.63% | -1.96% | 5.67% | 5.68% | -11.04% | 2.35% | -13.11% | 4.24% | -26.73% |
| 2018 | 9.73% | 1.39% | 9.02% | -10.78% | 17.42% | -6.22% | -6.63% | 12.02% | -5.37% | -27.32% | 34.40% | -0.19% | 14.98% |
| 2017 | -0.73% | 21.70% | 1.33% | 7.25% | 7.43% | -11.35% | 8.50% | 8.37% | 4.95% | 7.08% | 19.82% | 21.44% | 140.40% |
| 2016 | 19.55% | -11.53% | 29.65% | -7.79% | 11.23% | 4.50% | -9.00% | -20.29% | 6.99% | -15.78% | -1.76% | 3.28% | -2.53% |
| 2015 | -7.74% | -6.13% | 3.09% | 7.83% | 42.50% | 37.74% | -29.53% | -15.08% | 6.58% | -5.93% | 2.36% | -7.90% | 6.90% |
| 2014 | -2.62% | -2.96% | -2.64% | -0.14% | -16.14% | 0.17% | 4.42% | 7.33% | 13.66% | -6.94% | -4.45% | 1.90% | -10.93% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 78, 069620.KS is among the top 22% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Daewoong Pharma (069620.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Daewoong Pharma provided a 0.37% dividend yield over the last twelve months, with an annual payout of ₩600.00 per share.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | ₩600.00 | ₩600.00 | ₩0.00 | ₩600.00 | ₩600.00 | ₩600.00 | ₩600.00 | ₩600.00 | ₩600.00 | ₩600.00 | ₩700.00 | ₩700.00 |
Dividend yield | 0.37% | 0.47% | 0.00% | 0.38% | 0.41% | 0.36% | 0.44% | 0.32% | 0.36% | 0.87% | 0.98% | 1.04% |
Monthly Dividends
The table displays the monthly dividend distributions for Daewoong Pharma. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | |||||
| 2024 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩600.00 | ₩600.00 |
| 2023 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 |
| 2022 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩600.00 | ₩600.00 |
| 2021 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩600.00 | ₩600.00 |
| 2020 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩600.00 | ₩600.00 |
| 2019 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩600.00 | ₩600.00 |
| 2018 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩600.00 | ₩600.00 |
| 2017 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩600.00 | ₩600.00 |
| 2016 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩600.00 | ₩600.00 |
| 2015 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩700.00 | ₩700.00 |
| 2014 | ₩700.00 | ₩700.00 |
Dividend Yield & Payout
Dividend Yield
Daewoong Pharma has a dividend yield of 0.37%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.
Payout Ratio
Daewoong Pharma has a payout ratio of 17.94%, which is below the market average. This means Daewoong Pharma returns a smaller proportion of its earnings to shareholders as dividends, suggesting it retains a higher portion for reinvestment, growth, or debt payment.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Daewoong Pharma. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Daewoong Pharma was 76.97%, occurring on May 18, 2012. Recovery took 371 trading sessions.
The current Daewoong Pharma drawdown is 40.39%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -76.97% | Apr 1, 2008 | 1034 | May 18, 2012 | 371 | Nov 18, 2013 | 1405 |
| -70.61% | Apr 11, 2018 | 476 | Mar 19, 2020 | 188 | Dec 21, 2020 | 664 |
| -66.28% | Dec 22, 2020 | 629 | Jul 10, 2023 | — | — | — |
| -55.07% | Jun 29, 2015 | 359 | Dec 8, 2016 | 228 | Nov 15, 2017 | 587 |
| -39.18% | Apr 17, 2006 | 38 | Jun 13, 2006 | 91 | Oct 25, 2006 | 129 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Daewoong Pharma over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Daewoong Pharma, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -18.3%.
Valuation
The Valuation section provides an overview of how Daewoong Pharma is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 069620.KS compared to other companies in the Drug Manufacturers - Specialty & Generic industry. 069620.KS currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 069620.KS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 069620.KS has a P/S ratio of 1.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 069620.KS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 069620.KS has a P/B value of 2.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |